SuperworthWarby Parker EPS WRBY
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- $0.07
- Latest quarter, Q2 FY26
- $0.04
- Fiscal year 2025
- $0.02
Warby Parker's earnings per share was $0.07 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was $0.04.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $0.02 | n/a |
| FY2024 | −$0.17 | n/a |
| FY2023 | −$0.54 | n/a |
| FY2022 | −$0.97 | n/a |
| FY2021 | −$2.23 | n/a |
| FY2020 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.04 | n/a | $0.07 | |
| Q1 FY26 | $0.03 | +0% | $0.02 | |
| Q4 FY25 | −$0.05 | n/a | $0.02 | |
| Q3 FY25 | $0.05 | n/a | $0.01 | |
| Q2 FY25 | −$0.01 | n/a | −$0.07 | |
| Q1 FY25 | $0.03 | n/a | −$0.12 | |
| Q4 FY24 | −$0.06 | n/a | −$0.17 | |
| Q3 FY24 | −$0.03 | n/a | −$0.27 | |
| Q2 FY24 | −$0.06 | n/a | −$0.39 | |
| Q1 FY24 | −$0.02 | n/a | −$0.47 | |
| Q4 FY23 | −$0.16 | n/a | −$0.54 | |
| Q3 FY23 | −$0.15 | n/a | −$0.56 |
Against its peers
Companies in Medical - Instruments & Supplies nearest Warby Parker's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| WRBYWarby Parker | $0.07 | |
| ATRCAtriCure | $0.21 | |
| NVSTEnvista | $0.58 | +81% a year |
| ICUIICU Medical | $1.18 | |
| BMIBadger Meter | $4.28 | −8% a year |
| UFPTUFP Technologies | $9.28 | +8% a year |
| VNTVontier | $2.41 | −8% a year |
| INSPInspire Medical Systems | $4.62 | +166% a year |
| LMATLemaitre Vascular | $2.85 | +38% a year |
| HAEHaemonetics | $2.04 | −38% a year |
| MMSIMerit Medical Systems | $2.42 | +23% a year |
| Peer median | $2.42 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Warby Parker
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.